Boston Scientific (BSX)
Boston Scientific on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus.
40.7M
Short interest
settlement 2026-10-15
2.6
Days to cover
+0.7 days vs prior
36.8%
Short share of volume
2026-11-02
11,203
Fails to deliver
settlement 2026-10-09
Wed 3 Feb
Next earnings
estimated date
$200K
Insider flow, 90 days
2 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in BSX is 40,708,019 shares, down 5,796,750 shares over the last month. Over the last 48 readings it ranged from 10,449,826 shares (31 January 2025) to 57,491,117 shares (29 May 2026). At the reported average volume of 15.7M shares a day that is 2.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bsx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 40,708,019 | -1.7% | 15,744,920 | 2.59 |
| 2026-09-30 | 41,410,512 | -10.9% | 21,984,746 | 1.88 |
| 2026-09-15 | 46,504,769 | -3.5% | 19,748,214 | 2.35 |
| 2026-08-31 | 48,173,758 | +74.4% | 21,036,931 | 2.29 |
| 2026-08-14 | 27,617,554 | +24.0% | 17,642,161 | 1.57 |
| 2026-07-31 | 22,276,201 | -21.2% | 21,974,600 | 1.01 |
| 2026-07-15 | 28,281,040 | +1.2% | 16,776,824 | 1.69 |
| 2026-06-30 | 27,938,624 | -6.1% | 23,398,673 | 1.19 |
| 2026-06-15 | 29,750,309 | -48.3% | 20,617,498 | 1.44 |
| 2026-05-29 | 57,491,117 | +83.0% | 25,507,630 | 2.25 |
| 2026-05-15 | 31,423,298 | +9.7% | 17,713,835 | 1.77 |
| 2026-04-30 | 28,642,737 | +11.8% | 21,126,230 | 1.36 |
| 2026-04-15 | 25,614,558 | +8.9% | 14,196,053 | 1.80 |
| 2026-03-31 | 23,529,218 | -7.5% | 16,507,632 | 1.43 |
| 2026-03-13 | 25,441,563 | -3.1% | 12,874,974 | 1.98 |
| 2026-02-27 | 26,261,043 | -1.4% | 13,520,963 | 1.94 |
| 2026-02-13 | 26,641,433 | -5.8% | 27,986,053 | 1.00 |
| 2026-01-30 | 28,281,105 | +20.8% | 14,359,024 | 1.97 |
| 2026-01-15 | 23,415,429 | +17.0% | 10,294,612 | 2.27 |
| 2025-12-31 | 20,010,940 | +4.5% | 8,454,112 | 2.37 |
| 2025-12-15 | 19,144,680 | +2.2% | 10,117,284 | 1.89 |
| 2025-11-28 | 18,734,072 | -11.1% | 9,892,043 | 1.89 |
| 2025-11-14 | 21,076,004 | +8.3% | 7,709,891 | 2.73 |
| 2025-10-31 | 19,453,503 | -0.9% | 8,516,401 | 2.28 |
| 2025-10-15 | 19,634,328 | +1.2% | 9,665,641 | 2.03 |
| 2025-09-30 | 19,401,596 | +2.0% | 13,301,110 | 1.46 |
| 2025-09-15 | 19,015,043 | +0.1% | 8,063,283 | 2.36 |
| 2025-08-29 | 18,992,023 | +2.1% | 5,896,500 | 3.22 |
| 2025-08-15 | 18,604,681 | +14.3% | 5,858,844 | 3.18 |
| 2025-07-31 | 16,270,253 | -16.9% | 8,240,283 | 1.97 |
| 2025-07-15 | 19,569,890 | +2.7% | 6,815,925 | 2.87 |
| 2025-06-30 | 19,047,389 | +8.9% | 7,945,648 | 2.40 |
| 2025-06-13 | 17,494,239 | +2.8% | 8,163,319 | 2.14 |
| 2025-05-30 | 17,022,220 | +1.6% | 7,506,244 | 2.27 |
| 2025-05-15 | 16,752,863 | +6.6% | 6,046,738 | 2.77 |
| 2025-04-30 | 15,713,241 | +8.4% | 8,040,940 | 1.95 |
| 2025-04-15 | 14,494,253 | +10.7% | 12,220,075 | 1.19 |
| 2025-03-31 | 13,097,416 | +3.8% | 6,985,310 | 1.87 |
| 2025-03-14 | 12,623,573 | -1.9% | 9,484,266 | 1.33 |
| 2025-02-28 | 12,873,554 | +12.4% | 8,036,802 | 1.60 |
| 2025-02-14 | 11,456,307 | +9.6% | 6,498,679 | 1.76 |
| 2025-01-31 | 10,449,826 | -27.4% | 6,328,021 | 1.65 |
| 2025-01-15 | 14,397,966 | -0.9% | 5,362,048 | 2.69 |
| 2024-12-31 | 14,523,331 | +17.8% | 5,104,130 | 2.85 |
| 2024-12-13 | 12,327,400 | +0.7% | 3,745,322 | 3.29 |
| 2024-11-29 | 12,247,383 | +11.1% | 5,655,508 | 2.17 |
| 2024-11-15 | 11,024,434 | -14.6% | 5,742,863 | 1.92 |
| 2024-10-31 | 12,914,627 | +14.2% | 8,253,816 | 1.56 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of BSX volume is 36.8%, up 9.2 points over the last five sessions. Over the last 30 readings it ranged from 22.7% (27 October 2026) to 60.3% (2 October 2026). The latest reading is 4.4 points below the 30-session average of 41.2%, on 10.0M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 3.7M | 10.0M | 36.8% | 22,877 |
| 2026-10-30 | 2.0M | 7.5M | 27.0% | 56,037 |
| 2026-10-29 | 3.4M | 14.3M | 23.5% | 169,658 |
| 2026-10-28 | 9.7M | 25.8M | 37.8% | 168,979 |
| 2026-10-27 | 1.3M | 5.7M | 22.7% | 3,217 |
| 2026-10-26 | 1.5M | 5.3M | 27.5% | 11,643 |
| 2026-10-23 | 2.0M | 3.8M | 52.6% | 8,139 |
| 2026-10-22 | 3.0M | 5.6M | 53.8% | 19,317 |
| 2026-10-21 | 2.8M | 5.5M | 51.2% | 9,128 |
| 2026-10-20 | 2.6M | 6.3M | 41.9% | 26,783 |
| 2026-10-19 | 1.9M | 5.5M | 35.4% | 17,897 |
| 2026-10-16 | 2.0M | 4.9M | 41.4% | 2,193 |
| 2026-10-15 | 1.8M | 5.3M | 34.1% | 6,126 |
| 2026-10-14 | 2.3M | 5.2M | 44.5% | 8,518 |
| 2026-10-13 | 2.0M | 4.8M | 41.7% | 19,522 |
| 2026-10-12 | 2.3M | 5.6M | 41.2% | 30,296 |
| 2026-10-09 | 1.6M | 5.2M | 30.5% | 9,905 |
| 2026-10-08 | 2.8M | 7.0M | 41.0% | 6,193 |
| 2026-10-07 | 4.1M | 7.5M | 54.6% | 18,436 |
| 2026-10-06 | 2.4M | 5.2M | 45.6% | 28,038 |
| 2026-10-05 | 2.6M | 5.7M | 45.4% | 52,178 |
| 2026-10-02 | 4.6M | 7.7M | 60.3% | 43,208 |
| 2026-10-01 | 3.0M | 6.8M | 44.8% | 14,506 |
| 2026-09-30 | 2.2M | 6.9M | 32.1% | 14,654 |
| 2026-09-29 | 1.7M | 5.1M | 33.6% | 17,954 |
| 2026-09-28 | 2.0M | 4.6M | 44.4% | 7,847 |
| 2026-09-25 | 2.6M | 5.9M | 44.2% | 11,671 |
| 2026-09-24 | 1.9M | 3.9M | 47.6% | 6,241 |
| 2026-09-23 | 2.6M | 5.9M | 44.7% | 9,233 |
| 2026-09-22 | 2.9M | 5.5M | 53.3% | 14,073 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in BSX is 11,203 shares, up 10,254 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (4 August 2026) to 76,793 shares (18 June 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 11,203 | $42.04 | $471K |
| 2026-10-08 | 949 | $41.58 | $39K |
| 2026-10-07 | 12,344 | $42.19 | $521K |
| 2026-10-05 | 4 | $42.60 | $170 |
| 2026-09-28 | 2,138 | $43.92 | $94K |
| 2026-09-24 | 1,796 | $44.62 | $80K |
| 2026-09-22 | 701 | $43.72 | $31K |
| 2026-09-09 | 5,661 | $44.98 | $255K |
| 2026-09-08 | 24,075 | $47.80 | $1.2M |
| 2026-09-02 | 5,542 | $48.08 | $266K |
| 2026-08-24 | 3,497 | $50.37 | $176K |
| 2026-08-20 | 28,890 | $52.01 | $1.5M |
| 2026-08-12 | 51 | $51.19 | $3K |
| 2026-08-10 | 100 | $49.31 | $5K |
| 2026-08-04 | 1 | $48.43 | $48 |
| 2026-08-03 | 200 | $46.73 | $9K |
| 2026-07-29 | 11,681 | $46.06 | $538K |
| 2026-07-20 | 273 | $44.03 | $12K |
| 2026-07-15 | 38 | $42.63 | $2K |
| 2026-07-06 | 13,769 | $45.14 | $622K |
| 2026-07-02 | 2,224 | $43.06 | $96K |
| 2026-07-01 | 35,826 | $42.68 | $1.5M |
| 2026-06-30 | 14,456 | $43.48 | $629K |
| 2026-06-24 | 44 | $45.60 | $2K |
| 2026-06-22 | 1,381 | $45.29 | $63K |
| 2026-06-18 | 76,793 | $44.95 | $3.5M |
| 2026-06-15 | 72 | $46.91 | $3K |
| 2026-06-12 | 21 | $47.17 | $991 |
| 2026-06-11 | 520 | $48.34 | $25K |
| 2026-06-08 | 37,159 | $48.55 | $1.8M |
Insider trades
SEC Form 4, newest first. JSONInsiders at BSX reported 2 open-market buys worth $200K in the last 90 days and no open-market sells. Latest filing: O'Connor Padraig Andrew (EVP, Global Operations) on 2026-09-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | O'Connor Padraig Andrew | EVP, Global Operations | Tax withholding | 567 | $48.37 | $27K | 8K |
| 2026-09-02 | O'Connor Padraig Andrew | EVP, Global Operations | Exercise or conversion | 1K | $0.00 | $0 | 8K |
| 2026-08-25 | Morano Susan E | Director | Buy | 2K | $49.22 | $100K | 14K |
| 2026-08-11 | Woodworth Emily | SVP, Global Controller and CAO | Discretionary trade | 3K | $51.19 | $150K | 3K |
| 2026-08-10 | Monson Jonathan | EVP and CFO | Discretionary trade | 10K | $50.46 | $500K | 10K |
| 2026-08-05 | Habiger David C | Director | Buy | 2K | $47.59 | $100K | 17K |
| 2026-08-04 | Habiger David C | Director | Buy | 140 | $48.59 | $7K | 15K |
| 2026-08-03 | Habiger David C | Director | Buy | 1K | $48.07 | $50K | 15K |
| 2026-08-03 | Mahoney Michael F | Chairman, President & CEO | Discretionary trade | 22K | $48.43 | $1.1M | 22K |
| 2026-08-03 | Mahoney Michael F | Chairman, President & CEO | Buy | 186K | $48.33 | $9.0M | 1.6M |
| 2026-07-31 | LUDWIG EDWARD J | Director | Buy | 5K | $45.48 | $227K | 30K |
| 2026-07-31 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | Discretionary trade | 64K | $46.73 | $3.0M | 64K |
| 2026-07-01 | Monson Jonathan | EVP and CFO | Tax withholding | 1K | $43.06 | $43K | 39K |
| 2026-07-01 | Monson Jonathan | EVP and CFO | Exercise or conversion | 2K | $0.00 | $0 | 40K |
| 2026-05-28 | Mahoney Michael F | Chairman, President & CEO | Gift | 387K | $0.00 | $0 | 0 |
| 2026-05-20 | Pegus Cheryl | Director | Buy | 2K | $56.49 | $100K | 2K |
| 2026-05-20 | LUDWIG EDWARD J | Director | Buy | 4K | $56.68 | $203K | 25K |
| 2026-05-20 | Habiger David C | Director | Buy | 2K | $55.92 | $126K | 14K |
| 2026-05-19 | Habiger David C | Director | Buy | 2K | $56.95 | $125K | 12K |
| 2026-05-07 | Zane Ellen M | Director | Grant | 4K | $0.00 | $0 | 28K |
| 2026-05-07 | WICHMANN DAVID S | Director | Grant | 4K | $0.00 | $0 | 45K |
| 2026-05-07 | Weber Christophe Pierre | Director | Grant | 1K | $0.00 | $0 | 4K |
| 2026-05-07 | Weber Christophe Pierre | Director | Grant | 2K | $0.00 | $0 | 3K |
| 2026-05-07 | Morano Susan E | Director | Grant | 1K | $0.00 | $0 | 12K |
| 2026-05-07 | Morano Susan E | Director | Grant | 4K | $0.00 | $0 | 10K |
| 2026-05-07 | Mega Jessica L | Director | Grant | 4K | $0.00 | $0 | 12K |
| 2026-05-07 | LUDWIG EDWARD J | Director | Grant | 4K | $0.00 | $0 | 22K |
| 2026-05-07 | Habiger David C | Director | Grant | 4K | $0.00 | $0 | 9K |
| 2026-05-02 | O'Connor Padraig Andrew | EVP, Global Operations | Tax withholding | 872 | $56.50 | $49K | 7K |
| 2026-05-02 | O'Connor Padraig Andrew | EVP, Global Operations | Exercise or conversion | 2K | $0.00 | $0 | 8K |
| 2026-05-02 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Tax withholding | 1K | $56.50 | $57K | 57K |
| 2026-05-02 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Exercise or conversion | 2K | $0.00 | $0 | 58K |
| 2026-03-02 | Morano Susan E | Director | Grant | 24 | $0.00 | $0 | 7K |
| 2026-03-02 | Weber Christophe Pierre | Director | Grant | 323 | $0.00 | $0 | 879 |
| 2026-03-02 | Weber Christophe Pierre | Director | Grant | 556 | $0.00 | $0 | 556 |
| 2026-03-01 | Woodworth Emily | SVP, Global Controller and CAO | Tax withholding | 372 | $76.85 | $29K | 3K |
| 2026-03-01 | Woodworth Emily | SVP, Global Controller and CAO | Exercise or conversion | 838 | $0.00 | $0 | 3K |
| 2026-02-19 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Discretionary trade | 7K | $75.76 | $519K | 20K |
| 2026-02-16 | Woodworth Emily | SVP, Global Controller and CAO | Tax withholding | 283 | $74.73 | $21K | 2K |
| 2026-02-16 | Woodworth Emily | SVP, Global Controller and CAO | Exercise or conversion | 637 | $0.00 | $0 | 3K |
| 2026-02-16 | O'Sullivan Miriam | SVP, Chief HR Officer | Tax withholding | 291 | $74.73 | $22K | 17K |
| 2026-02-16 | O'Sullivan Miriam | SVP, Chief HR Officer | Exercise or conversion | 990 | $0.00 | $0 | 18K |
| 2026-02-16 | O'Connor Padraig Andrew | EVP, Global Operations | Tax withholding | 339 | $74.73 | $25K | 6K |
| 2026-02-16 | O'Connor Padraig Andrew | EVP, Global Operations | Exercise or conversion | 905 | $0.00 | $0 | 6K |
| 2026-02-16 | Monson Jonathan | EVP and CFO | Tax withholding | 440 | $74.73 | $33K | 38K |
| 2026-02-16 | Monson Jonathan | EVP and CFO | Exercise or conversion | 990 | $0.00 | $0 | 38K |
| 2026-02-16 | Mahoney Michael F | Chairman, President & CEO | Tax withholding | 8K | $74.73 | $588K | 1.6M |
| 2026-02-16 | Mahoney Michael F | Chairman, President & CEO | Exercise or conversion | 16K | $0.00 | $0 | 1.6M |
| 2026-02-16 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | Tax withholding | 2K | $74.73 | $135K | 214K |
| 2026-02-16 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | Exercise or conversion | 4K | $0.00 | $0 | 216K |
| 2026-02-16 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Tax withholding | 1K | $74.73 | $92K | 56K |
| 2026-02-16 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Exercise or conversion | 3K | $0.00 | $0 | 57K |
| 2026-02-16 | Brown Vance R | EVP, GC and Corp. Secretary | Tax withholding | 890 | $74.73 | $67K | 54K |
| 2026-02-16 | Brown Vance R | EVP, GC and Corp. Secretary | Exercise or conversion | 2K | $0.00 | $0 | 55K |
| 2026-02-14 | Woodworth Emily | SVP, Global Controller and CAO | Tax withholding | 296 | $74.73 | $22K | 2K |
| 2026-02-14 | Woodworth Emily | SVP, Global Controller and CAO | Exercise or conversion | 661 | $0.00 | $0 | 2K |
| 2026-02-14 | O'Sullivan Miriam | SVP, Chief HR Officer | Tax withholding | 329 | $74.73 | $25K | 17K |
| 2026-02-14 | O'Sullivan Miriam | SVP, Chief HR Officer | Exercise or conversion | 1K | $0.00 | $0 | 17K |
| 2026-02-14 | O'Connor Padraig Andrew | EVP, Global Operations | Tax withholding | 449 | $74.73 | $34K | 6K |
| 2026-02-14 | O'Connor Padraig Andrew | EVP, Global Operations | Exercise or conversion | 1K | $0.00 | $0 | 6K |
| 2026-02-14 | Monson Jonathan | EVP and CFO | Tax withholding | 470 | $74.73 | $35K | 37K |
| 2026-02-14 | Monson Jonathan | EVP and CFO | Exercise or conversion | 1K | $0.00 | $0 | 38K |
| 2026-02-14 | Mahoney Michael F | Chairman, President & CEO | Tax withholding | 8K | $74.73 | $597K | 1.6M |
| 2026-02-14 | Mahoney Michael F | Chairman, President & CEO | Exercise or conversion | 17K | $0.00 | $0 | 1.6M |
| 2026-02-14 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | Tax withholding | 2K | $74.73 | $149K | 212K |
| 2026-02-14 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | Exercise or conversion | 4K | $0.00 | $0 | 214K |
| 2026-02-14 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Tax withholding | 2K | $74.73 | $115K | 54K |
| 2026-02-14 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Exercise or conversion | 3K | $0.00 | $0 | 56K |
| 2026-02-14 | Brown Vance R | EVP, GC and Corp. Secretary | Tax withholding | 895 | $74.73 | $67K | 53K |
| 2026-02-14 | Brown Vance R | EVP, GC and Corp. Secretary | Exercise or conversion | 2K | $0.00 | $0 | 54K |
| 2026-02-13 | Mahoney Michael F | Chairman, President & CEO | Grant | 132K | $0.00 | $0 | 1.7M |
| 2026-02-13 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | Grant | 35K | $0.00 | $0 | 240K |
| 2026-02-13 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Grant | 25K | $0.00 | $0 | 76K |
| 2026-02-13 | Brown Vance R | EVP, GC and Corp. Secretary | Grant | 15K | $0.00 | $0 | 64K |
| 2026-02-13 | Woodworth Emily | SVP, Global Controller and CAO | Tax withholding | 690 | $74.73 | $52K | 2K |
| 2026-02-13 | Woodworth Emily | SVP, Global Controller and CAO | Exercise or conversion | 1K | $0.00 | $0 | 2K |
| 2026-02-13 | O'Sullivan Miriam | SVP, Chief HR Officer | Tax withholding | 200 | $74.73 | $15K | 16K |
| 2026-02-13 | O'Sullivan Miriam | SVP, Chief HR Officer | Exercise or conversion | 588 | $0.00 | $0 | 16K |
| 2026-02-13 | O'Connor Padraig Andrew | EVP, Global Operations | Tax withholding | 199 | $74.73 | $15K | 5K |
| 2026-02-13 | O'Connor Padraig Andrew | EVP, Global Operations | Exercise or conversion | 500 | $0.00 | $0 | 5K |
| 2026-02-13 | Monson Jonathan | EVP and CFO | Tax withholding | 788 | $74.73 | $59K | 37K |
| 2026-02-13 | Monson Jonathan | EVP and CFO | Exercise or conversion | 2K | $0.00 | $0 | 38K |
| 2026-02-13 | Mahoney Michael F | Chairman, President & CEO | Tax withholding | 132K | $74.73 | $9.9M | 1.6M |
| 2026-02-13 | Mahoney Michael F | Chairman, President & CEO | Exercise or conversion | 9K | $0.00 | $0 | 1.7M |
| 2026-02-13 | Mahoney Michael F | Chairman, President & CEO | Grant | 132K | $0.00 | $0 | 1.6M |
| 2026-02-13 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | Tax withholding | 33K | $74.73 | $2.5M | 209K |
| 2026-02-13 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | Exercise or conversion | 3K | $0.00 | $0 | 242K |
| 2026-02-13 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | Grant | 35K | $0.00 | $0 | 205K |
| 2026-02-13 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Tax withholding | 25K | $74.73 | $1.9M | 53K |
| 2026-02-13 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Exercise or conversion | 2K | $0.00 | $0 | 78K |
| 2026-02-13 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | Grant | 25K | $0.00 | $0 | 50K |
| 2026-02-13 | Brown Vance R | EVP, GC and Corp. Secretary | Tax withholding | 13K | $74.73 | $956K | 52K |
| 2026-02-13 | Brown Vance R | EVP, GC and Corp. Secretary | Exercise or conversion | 1K | $0.00 | $0 | 65K |
| 2026-02-13 | Brown Vance R | EVP, GC and Corp. Secretary | Grant | 15K | $0.00 | $0 | 49K |
| 2026-02-12 | O'Sullivan Miriam | SVP, Chief HR Officer | Tax withholding | 338 | $74.12 | $25K | 15K |
| 2026-02-12 | O'Sullivan Miriam | SVP, Chief HR Officer | Exercise or conversion | 961 | $0.00 | $0 | 16K |
| 2026-02-12 | Woodworth Emily | SVP, Global Controller and CAO | Tax withholding | 242 | $74.12 | $18K | 951 |
| 2026-02-12 | Woodworth Emily | SVP, Global Controller and CAO | Exercise or conversion | 481 | $0.00 | $0 | 1K |
| 2026-02-12 | O'Connor Padraig Andrew | EVP, Global Operations | Tax withholding | 457 | $74.12 | $34K | 4K |
| 2026-02-12 | O'Connor Padraig Andrew | EVP, Global Operations | Exercise or conversion | 1K | $0.00 | $0 | 5K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON7 Form 144 notices on file for BSX worth $28.3M at the prices reported; 0 in the last 90 days worth $0. Latest: MICHAEL F MAHONEY filed on 2026-02-02 to sell 160,901 shares ($15.0M) from 2026-02-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-02-02 | MICHAEL F MAHONEYOfficer, Director | 161K | $15.0M | 0.011% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-01 | ARTHUR C BUTCHEROfficer | 17K | $1.8M | 0.001% | 2025-12-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-06 | Zane Ellen MDirector | 3K | $284K | 0.000% | 2025-11-06 | Wells Fargo Clearing Services |
| 2025-11-03 | JOSEPH M FITZGERALDOfficer | 50K | $5.0M | 0.003% | 2025-11-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-28 | Zane Ellen MDirector | 3K | $297K | 0.000% | 2025-10-28 | Wells Fargo Clearing Services |
| 2025-10-27 | Zane Ellen MDirector | 10K | $1.0M | 0.001% | 2025-10-27 | Wells Fargo Clearing Services |
| 2025-10-01 | JOSEPH M FITZGERALDOfficer | 50K | $4.9M | 0.003% | 2025-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of BSX in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (111,127,205 shares), filed 2026-04-29 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-06 | 13G/Ano. 6 | FMR LLCparent holding company | 46.4M | 3.1% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 6 | Abigail P. Johnsonindividual | 46.4M | 3.1% | 2026-06-30 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 111.1M | 7.5% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 11 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding BSX at their latest 13F. JSON9 of the 30 tracked managers held BSX at their latest 13F, $2.90B in total at quarter-end prices. D. E. Shaw & Co. is the largest at $1.09B (0.5% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 25.5M | $1.09B | 0.52% | +1.1M |
| Two Sigma Investments | 2026-06-30 | 19.4M | $826.2M | 0.60% | +9.9M |
| AQR Capital Management | 2026-06-30 | 9.7M | $413.2M | 0.14% | +4.4M |
| Citadel Advisors | 2026-06-30 | 5.0M | $212.9M | 0.02% | +770K |
| Millennium Management | 2026-06-30 | 5.4M | $210.7M | 0.08% | +1.1M |
| Renaissance Technologies | 2026-06-30 | 2.4M | $102.9M | 0.14% | -740K |
| Bridgewater Associates | 2026-06-30 | 442K | $18.9M | 0.08% | +365K |
| Point72 Asset Management | 2026-06-30 | 365K | $15.6M | 0.02% | -3.3M |
| Fisher Asset Management | 2026-06-30 | 334K | $14.2M | 0.00% | -117K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Boston Scientific reported revenue of $5.44B, up 7.5% from the same quarter a year earlier (0.61 diluted EPS). In FY 2025 it generated $4.53B of operating cash flow. As of 2026-06-30, cash was $539.0M against $1.71B of debt.
- Cash
- $539.0M
- Debt
- $1.71B
- Equity
- $24.93B
- Total assets
- $45.22B
- Shares outstanding
- 1,449,229,526
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $5.44B | n/a | n/a | 0.61 |
| Q1 FY 2026 | 2026-03-31 | $5.20B | n/a | n/a | 0.90 |
| Q4 FY 2025derived | 2025-12-31 | $5.29B | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $5.07B | n/a | n/a | 0.51 |
| Q2 FY 2025 | 2025-06-30 | $5.06B | n/a | n/a | 0.53 |
| Q1 FY 2025 | 2025-03-31 | $4.66B | n/a | n/a | 0.45 |
| Q4 FY 2024derived | 2024-12-31 | $4.56B | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $4.21B | n/a | n/a | 0.32 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $20.07B | n/a | $4.53B | $876.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $16.75B | n/a | $3.44B | $790.0M | n/a | $0 |
| FY 2023 | 2023-12-31 | $14.24B | n/a | $2.50B | $711.0M | n/a | $28.0M |
| FY 2022 | 2022-12-31 | $12.68B | n/a | $1.53B | $588.0M | $0 | $55.0M |
| FY 2021 | 2021-12-31 | $11.89B | n/a | $1.87B | $554.0M | $0 | $55.0M |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.
What this page is
Boston Scientific in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Boston Scientific (BSX), SEC CIK 885725, listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-02-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-06.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-28.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 885725Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
Other company pages
Datasets
Frequently Asked Questions
How much of BSX is sold short?
40,708,019 shares were held short at the 2026-10-15 settlement, 2.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is BSX's daily short volume?
On 2026-11-02, 3,687,965 of the 10,036,551 BSX shares reported to FINRA were sold short, 36.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does BSX have fails to deliver?
The SEC's latest file shows 11,203 BSX shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are BSX insiders buying or selling?
Insiders at BSX reported 2 open-market buys worth $200K in the last 90 days and no open-market sells. Latest filing: O'Connor Padraig Andrew (EVP, Global Operations) on 2026-09-02.
Have BSX insiders filed to sell?
7 Form 144 notices on file for BSX worth $28.3M at the prices reported; 0 in the last 90 days worth $0. Latest: MICHAEL F MAHONEY filed on 2026-02-02 to sell 160,901 shares ($15.0M) from 2026-02-02.
Who owns 5% or more of BSX?
1 holder reports 5% or more of BSX in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (111,127,205 shares), filed 2026-04-29 for an event on 2026-03-31.
What did BSX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Boston Scientific reported revenue of $5.44B, up 7.5% from the same quarter a year earlier (0.61 diluted EPS). In FY 2025 it generated $4.53B of operating cash flow. As of 2026-06-30, cash was $539.0M against $1.71B of debt.
Which tracked 13F managers own BSX?
9 of the 30 tracked 13F managers held BSX shares at their latest filing, $2.90B in all. The largest: D. E. Shaw & Co. (25.5M shares, $1.09B), Two Sigma Investments (19.4M shares, $826.2M), Cliff Asness's AQR Capital Management (9.7M shares, $413.2M), Ken Griffin's Citadel Advisors (5.0M shares, $212.9M), Izzy Englander's Millennium Management (5.4M shares, $210.7M), Renaissance Technologies (2.4M shares, $102.9M). The table above lists all 9.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.